Cerecor Inc (NASDAQ:CERC) Expected to Post Earnings of -$0.16 Per Share

Brokerages expect that Cerecor Inc (NASDAQ:CERC) will post earnings of ($0.16) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Cerecor’s earnings, with the lowest EPS estimate coming in at ($0.18) and the highest estimate coming in at ($0.14). Cerecor posted earnings of ($0.10) per share during the same quarter last year, which would indicate a negative year over year growth rate of 60%. The firm is expected to issue its next earnings report on Thursday, August 8th.

On average, analysts expect that Cerecor will report full year earnings of ($0.64) per share for the current fiscal year, with EPS estimates ranging from ($0.70) to ($0.59). For the next year, analysts anticipate that the firm will post earnings of ($0.64) per share, with EPS estimates ranging from ($0.65) to ($0.63). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover Cerecor.

Cerecor (NASDAQ:CERC) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. The business had revenue of $5.41 million during the quarter, compared to analyst estimates of $4.85 million. Cerecor had a negative net margin of 226.50% and a negative return on equity of 120.67%.



Several research analysts have issued reports on CERC shares. ValuEngine lowered shares of Vereit from a “buy” rating to a “hold” rating in a report on Friday. Maxim Group started coverage on shares of Entera Bio in a report on Tuesday, July 2nd. They set a “buy” rating and a $12.00 price target for the company. LADENBURG THALM/SH SH restated a “buy” rating and set a $8.00 price target on shares of Cerecor in a report on Tuesday, July 2nd. TheStreet lowered shares of Virtusa from a “b-” rating to a “c+” rating in a report on Wednesday, May 29th. Finally, HC Wainwright set a $28.00 price target on shares of Denali Therapeutics and gave the stock a “buy” rating in a report on Monday, July 15th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $9.67.

Cerecor stock traded down $0.02 during mid-day trading on Monday, hitting $4.60. 52,096 shares of the stock were exchanged, compared to its average volume of 284,378. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.91 and a current ratio of 0.95. Cerecor has a 12 month low of $2.71 and a 12 month high of $7.65. The firm’s fifty day moving average price is $5.10.

In related news, Director Armistice Capital, Llc acquired 12,587 shares of the stock in a transaction dated Monday, May 13th. The stock was bought at an average price of $4.85 per share, for a total transaction of $61,046.95. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Armistice Capital Master Fund acquired 10,000 shares of the stock in a transaction dated Friday, June 7th. The stock was bought at an average price of $4.88 per share, with a total value of $48,800.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 225,219 shares of company stock valued at $1,077,864. Company insiders own 64.30% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Opaleye Management Inc. bought a new stake in shares of Cerecor in the 4th quarter valued at $6,212,000. Geode Capital Management LLC increased its stake in shares of Cerecor by 50.7% in the 4th quarter. Geode Capital Management LLC now owns 94,990 shares of the company’s stock valued at $306,000 after acquiring an additional 31,951 shares in the last quarter. Spark Investment Management LLC increased its stake in shares of Cerecor by 60.5% in the 1st quarter. Spark Investment Management LLC now owns 83,000 shares of the company’s stock valued at $484,000 after acquiring an additional 31,290 shares in the last quarter. Tibra Equities Europe Ltd bought a new stake in shares of Cerecor in the 1st quarter valued at $210,000. Finally, BlackRock Inc. increased its stake in shares of Cerecor by 18.5% in the 4th quarter. BlackRock Inc. now owns 33,960 shares of the company’s stock valued at $109,000 after acquiring an additional 5,293 shares in the last quarter. Institutional investors own 53.90% of the company’s stock.

Cerecor Company Profile

Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device.

Featured Story: Can individual investors take part in an IPO?

Get a free copy of the Zacks research report on Cerecor (CERC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.